New eczema drug shows early promise in small trial
NCT ID NCT04643457
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 28 times
Summary
This early-stage study tested a new medicine called UCB9741 in 107 people, first in healthy volunteers and then in those with moderate-to-severe atopic dermatitis (eczema). The main goals were to check safety and see if the drug can improve skin symptoms. Researchers measured side effects and used a standard eczema severity score to track improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Up0089 101
London, United Kingdom
-
Up0089 103
Manchester, United Kingdom
-
Up0089 104
Liverpool, United Kingdom
-
Up0089 201
Leiden, Netherlands
-
Up0089 301
Sofia, Bulgaria
-
Up0089 303
Pleven, Bulgaria
-
Up0089 304
Sofia, Bulgaria
-
Up0089 407
Berlin, Germany
-
Up0089 408
Heidelberg, Germany
-
Up0089 410
Leipzig, Germany
Conditions
Explore the condition pages connected to this study.